Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer

PHASE3

Phase

TERMINATED

Status

100

Enrollment

INDUSTRY

Sponsor class

Stopped The preliminary data do not support the expected sustainable blood levels of triptorelin for a duration of 4 months in all patients.

Conditions

DRUG: Triptorelin (Decapeptyl®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study)

Ipsen